Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY
Therapeutic Promise of Proteinase-Activated Receptor-2 Antagonism in Joint Inflammation
Elizabeth B. Kelso, John C. Lockhart, Todd Hembrough, Lynette Dunning, Robin Plevin, Morley D. Hollenberg, Christian P. Sommerhoff, John S. McLean and William R. Ferrell
Journal of Pharmacology and Experimental Therapeutics March 2006, 316 (3) 1017-1024; DOI: https://doi.org/10.1124/jpet.105.093807
Elizabeth B. Kelso
Center for Rheumatic Diseases, Royal Infirmary, Glasgow, Scotland, United Kingdom (E.B.K., W.R.F.); School of Engineering and Science, University of Paisley, Paisley, Scotland, United Kingdom (J.C.L., L.D., J.S.M.); EntreMed, Inc., Rockville, Maryland (T.H.); Department of Physiology and Pharmacology, University of Strathclyde, Scotland, United Kingdom (R.P.); Canadian Institutes of Health Research Proteinases and Inflammation Network, Departments of Pharmacology and Therapeutics and Medicine, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada (M.D.H.); and Abteilung Klinische Chemie und Klinische Biochemie, Klinikumsstandort Innenstadt der Ludwig-Maximilians-Universität, Munich, Germany (C.P.S.)
John C. Lockhart
Center for Rheumatic Diseases, Royal Infirmary, Glasgow, Scotland, United Kingdom (E.B.K., W.R.F.); School of Engineering and Science, University of Paisley, Paisley, Scotland, United Kingdom (J.C.L., L.D., J.S.M.); EntreMed, Inc., Rockville, Maryland (T.H.); Department of Physiology and Pharmacology, University of Strathclyde, Scotland, United Kingdom (R.P.); Canadian Institutes of Health Research Proteinases and Inflammation Network, Departments of Pharmacology and Therapeutics and Medicine, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada (M.D.H.); and Abteilung Klinische Chemie und Klinische Biochemie, Klinikumsstandort Innenstadt der Ludwig-Maximilians-Universität, Munich, Germany (C.P.S.)
Todd Hembrough
Center for Rheumatic Diseases, Royal Infirmary, Glasgow, Scotland, United Kingdom (E.B.K., W.R.F.); School of Engineering and Science, University of Paisley, Paisley, Scotland, United Kingdom (J.C.L., L.D., J.S.M.); EntreMed, Inc., Rockville, Maryland (T.H.); Department of Physiology and Pharmacology, University of Strathclyde, Scotland, United Kingdom (R.P.); Canadian Institutes of Health Research Proteinases and Inflammation Network, Departments of Pharmacology and Therapeutics and Medicine, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada (M.D.H.); and Abteilung Klinische Chemie und Klinische Biochemie, Klinikumsstandort Innenstadt der Ludwig-Maximilians-Universität, Munich, Germany (C.P.S.)
Lynette Dunning
Center for Rheumatic Diseases, Royal Infirmary, Glasgow, Scotland, United Kingdom (E.B.K., W.R.F.); School of Engineering and Science, University of Paisley, Paisley, Scotland, United Kingdom (J.C.L., L.D., J.S.M.); EntreMed, Inc., Rockville, Maryland (T.H.); Department of Physiology and Pharmacology, University of Strathclyde, Scotland, United Kingdom (R.P.); Canadian Institutes of Health Research Proteinases and Inflammation Network, Departments of Pharmacology and Therapeutics and Medicine, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada (M.D.H.); and Abteilung Klinische Chemie und Klinische Biochemie, Klinikumsstandort Innenstadt der Ludwig-Maximilians-Universität, Munich, Germany (C.P.S.)
Robin Plevin
Center for Rheumatic Diseases, Royal Infirmary, Glasgow, Scotland, United Kingdom (E.B.K., W.R.F.); School of Engineering and Science, University of Paisley, Paisley, Scotland, United Kingdom (J.C.L., L.D., J.S.M.); EntreMed, Inc., Rockville, Maryland (T.H.); Department of Physiology and Pharmacology, University of Strathclyde, Scotland, United Kingdom (R.P.); Canadian Institutes of Health Research Proteinases and Inflammation Network, Departments of Pharmacology and Therapeutics and Medicine, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada (M.D.H.); and Abteilung Klinische Chemie und Klinische Biochemie, Klinikumsstandort Innenstadt der Ludwig-Maximilians-Universität, Munich, Germany (C.P.S.)
Morley D. Hollenberg
Center for Rheumatic Diseases, Royal Infirmary, Glasgow, Scotland, United Kingdom (E.B.K., W.R.F.); School of Engineering and Science, University of Paisley, Paisley, Scotland, United Kingdom (J.C.L., L.D., J.S.M.); EntreMed, Inc., Rockville, Maryland (T.H.); Department of Physiology and Pharmacology, University of Strathclyde, Scotland, United Kingdom (R.P.); Canadian Institutes of Health Research Proteinases and Inflammation Network, Departments of Pharmacology and Therapeutics and Medicine, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada (M.D.H.); and Abteilung Klinische Chemie und Klinische Biochemie, Klinikumsstandort Innenstadt der Ludwig-Maximilians-Universität, Munich, Germany (C.P.S.)
Christian P. Sommerhoff
Center for Rheumatic Diseases, Royal Infirmary, Glasgow, Scotland, United Kingdom (E.B.K., W.R.F.); School of Engineering and Science, University of Paisley, Paisley, Scotland, United Kingdom (J.C.L., L.D., J.S.M.); EntreMed, Inc., Rockville, Maryland (T.H.); Department of Physiology and Pharmacology, University of Strathclyde, Scotland, United Kingdom (R.P.); Canadian Institutes of Health Research Proteinases and Inflammation Network, Departments of Pharmacology and Therapeutics and Medicine, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada (M.D.H.); and Abteilung Klinische Chemie und Klinische Biochemie, Klinikumsstandort Innenstadt der Ludwig-Maximilians-Universität, Munich, Germany (C.P.S.)
John S. McLean
Center for Rheumatic Diseases, Royal Infirmary, Glasgow, Scotland, United Kingdom (E.B.K., W.R.F.); School of Engineering and Science, University of Paisley, Paisley, Scotland, United Kingdom (J.C.L., L.D., J.S.M.); EntreMed, Inc., Rockville, Maryland (T.H.); Department of Physiology and Pharmacology, University of Strathclyde, Scotland, United Kingdom (R.P.); Canadian Institutes of Health Research Proteinases and Inflammation Network, Departments of Pharmacology and Therapeutics and Medicine, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada (M.D.H.); and Abteilung Klinische Chemie und Klinische Biochemie, Klinikumsstandort Innenstadt der Ludwig-Maximilians-Universität, Munich, Germany (C.P.S.)
William R. Ferrell
Center for Rheumatic Diseases, Royal Infirmary, Glasgow, Scotland, United Kingdom (E.B.K., W.R.F.); School of Engineering and Science, University of Paisley, Paisley, Scotland, United Kingdom (J.C.L., L.D., J.S.M.); EntreMed, Inc., Rockville, Maryland (T.H.); Department of Physiology and Pharmacology, University of Strathclyde, Scotland, United Kingdom (R.P.); Canadian Institutes of Health Research Proteinases and Inflammation Network, Departments of Pharmacology and Therapeutics and Medicine, University of Calgary Faculty of Medicine, Calgary, Alberta, Canada (M.D.H.); and Abteilung Klinische Chemie und Klinische Biochemie, Klinikumsstandort Innenstadt der Ludwig-Maximilians-Universität, Munich, Germany (C.P.S.)
JPET articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|
Log in using your username and password
Purchase access
You may purchase access to this article. This will require you to create an account if you don't already have one.
In this issue
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY
Therapeutic Promise of Proteinase-Activated Receptor-2 Antagonism in Joint Inflammation
Elizabeth B. Kelso, John C. Lockhart, Todd Hembrough, Lynette Dunning, Robin Plevin, Morley D. Hollenberg, Christian P. Sommerhoff, John S. McLean and William R. Ferrell
Journal of Pharmacology and Experimental Therapeutics March 1, 2006, 316 (3) 1017-1024; DOI: https://doi.org/10.1124/jpet.105.093807
Research ArticleINFLAMMATION AND IMMUNOPHARMACOLOGY
Therapeutic Promise of Proteinase-Activated Receptor-2 Antagonism in Joint Inflammation
Elizabeth B. Kelso, John C. Lockhart, Todd Hembrough, Lynette Dunning, Robin Plevin, Morley D. Hollenberg, Christian P. Sommerhoff, John S. McLean and William R. Ferrell
Journal of Pharmacology and Experimental Therapeutics March 1, 2006, 316 (3) 1017-1024; DOI: https://doi.org/10.1124/jpet.105.093807
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement